Gene Therapy
Gene Therapy at a Crossroads: What the Sarepta Crisis Reveals — and What Comes Next
David Alvaro, Ph.D.; April Stanley, MS MBA; Sophie Lutter, Ph.D.
Pharma's Almanac
PAO-08-25-NI-02Aug 05, 2025
Viral Vectors
De-Risking Cell and Gene Therapies with Innovative Solutions: A Review for Leveraging a Proven Workhorse Technology in New Ways
Farzin Farzaneh, Ph.D.; Nicholas Ostrout, Ph.D.; Glenda Dickson, Ph.D.; David Darling, Ph.D.
ViroCell Biologics
PAO-06-25-CL-12Jul 31, 2025
Viral Vectors
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-09Jul 21, 2025
Gene Editing
What are the key ethical and regulatory considerations as gene editing technologies advance toward widespread clinical use?
Pharma's Almanac
PAO-05-25-RT-02Jun 17, 2025
OMVs and EVs
Driving Therapeutic Innovation with OMVs and EVs
Ola Tuvesson; Isa Lindgren, Ph.D.
NorthX Biologics
PAO-02-25-CL-09Mar 21, 2025
Advanced Therapies
Ensuring Nuclease Free Process Consumables for Biopharma Applications
Richard Fry
Sanisure
PAO-01-25-CL-05Jan 22, 2025
Sustainability
Synthetic DNA Delivers a Sustainable Future for Genetic Medicines
Touchlight
PAO-01-25-CL-04Jan 07, 2025
Nonviral Delivery
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA
Lisa Caproni
Touchlight
PAO-12-24-CL-4Dec 16, 2024
CRISPR
The Groundbreaking Potential of CRISPR Gene Editing
Olivia Newton-John Cancer Research Institute
PAO-10-24-RTM-09Nov 05, 2024
CDMO
Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO
Janet Hoogstraate, Ph.D.
NorthX Biologics
PAO-10-24-CL-07Oct 07, 2024
RNA
Optimized Residual dsRNA Detection for mRNA Therapeutics
Eunseo (Ency) Lee, Ph.D; Namhyun Kim; Hwanjun Yoon, Ph.D.; Sukhwan Kim; Ahyeon Hwang
Samsung Biologics
PAO-09-24-CL-07Sep 30, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01Sep 30, 2024
Protein Degradation
PROTACS: Upgrading Small Molecule Inhibitors
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-24-NI-02Jun 11, 2024
Immuno-Oncology
Building Multiple Platforms to Address Difficult-to-Treat Cancers
Derek Hennecke
Inceptor Bio
PAO-05-22-R250-09May 24, 2022
Pharma's Almanac
The Evolution and the Future of Pharma
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-22-R250-07Mar 08, 2022
Cell and Gene Therapy
Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform
Shailesh Maingi; Mike Nicholson, Ph.D.
Inceptor Bio
PAO-01-22-R250-15Jan 31, 2022
Cell Therapy
Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure
Chris McClain
Be The Match BioTherapies
PAO-09-21-CL-04Sep 09, 2021
mRNA Therapies
Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery
Shiksha Mantri, Ph.D.
MilliporeSigma
PAO-06-21-CL-08Jun 16, 2021
Cell and Gene Therapy
Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies
David Y. H. Chang, Ph.D.
WuXi Advanced Therapies
PAO-05-21-CL-05May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01Mar 16, 2021